Rankings
▼
Calendar
CMMB Q3 2024 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena
CMMB
Chemomab Therapeutics Ltd.
$12M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$4M
Net Income
-$3M
EPS (Diluted)
$-0.80
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
$0
Free Cash Flow
$0
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$21M
Total Liabilities
$5M
Stockholders' Equity
$16M
Cash & Equivalents
$7M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$18,938
+100.0%
Operating Income
-$4M
-$4M
+15.0%
Net Income
-$3M
-$4M
+14.4%
← FY 2024
All Quarters
Q4 2024 →